Multimarker Risk Assessment Including Osteoprotegerin and CXCL16 in Acute Coronary Syndromes | Zendy

Anna Jansson | Zendy; Marianne Hartford | Zendy; Torbjørn Omland | Zendy; Thomas Karlsson | Zendy; Per Lindmarker | Zendy; Johan Herlitz | Zendy; Thor Ueland | Zendy; Pål Aukrust | Zendy; Kenneth Caidahl | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Multimarker Risk Assessment Including Osteoprotegerin and CXCL16 in Acute Coronary Syndromes

Author(s) -

Anna Jansson,

Marianne Hartford,

Torbjørn Omland,

Thomas Karlsson,

Per Lindmarker,

Johan Herlitz,

Thor Ueland,

Pål Aukrust,

Kenneth Caidahl

Publication year - 2012

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.112.300326

Subject(s) - medicine , osteoprotegerin , cxcl16 , cardiology , quartile , hazard ratio , heart failure , acute coronary syndrome , ejection fraction , proportional hazards model , framingham risk score , diabetes mellitus , myocardial infarction , endocrinology , inflammation , confidence interval , receptor , disease , chemokine , chemokine receptor , activator (genetics)

CXCL16 and osteoprotegerin (OPG) both predict mortality in acute coronary syndromes. We hypothesized that a combination of CXCL16 and OPG concentrations would add prognostic information to the Global Registry of Acute Coronary Events (GRACE) score in patients hospitalized for acute coronary syndromes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research